Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Sold Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $15,001 and $50,000 in Crinetics Pharmaceuticals stock on July 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Crinetics Pharmaceuticals Price Performance

Shares of NASDAQ CRNX remained flat at $84.95 during trading on Tuesday. Crinetics Pharmaceuticals, Inc. has a twelve month low of $30.25 and a twelve month high of $85.01. The company’s 50-day moving average price is $79.85 and its 200 day moving average price is $52.46. The stock has a market capitalization of $9.01 billion, a P/E ratio of -16.86 and a beta of 0.08.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.04. Crinetics Pharmaceuticals had a negative net margin of 1,189.88% and a negative return on equity of 44.22%. The firm had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $14.84 million. During the same quarter in the previous year, the company posted ($1.23) EPS. The company’s revenue was up 2336.9% compared to the same quarter last year. As a group, equities analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -4.83 earnings per share for the current year.

Institutional Trading of Crinetics Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Crinetics Pharmaceuticals in the second quarter valued at approximately $365,179,000. Wellington Management Group LLP grew its stake in shares of Crinetics Pharmaceuticals by 44.3% in the third quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company’s stock worth $349,110,000 after acquiring an additional 2,574,683 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Crinetics Pharmaceuticals by 20.2% during the fourth quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company’s stock worth $322,736,000 after acquiring an additional 1,163,000 shares during the period. Jupiter Topco LLC acquired a new stake in shares of Crinetics Pharmaceuticals in the second quarter valued at $170,509,000. Finally, Janus Henderson Group PLC boosted its holdings in Crinetics Pharmaceuticals by 1.8% in the first quarter. Janus Henderson Group PLC now owns 4,520,251 shares of the company’s stock valued at $164,227,000 after purchasing an additional 79,560 shares during the period. Institutional investors and hedge funds own 98.51% of the company’s stock.

Insider Buying and Selling at Crinetics Pharmaceuticals

In related news, Director Stephanie Okey sold 6,900 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the transaction, the director directly owned 6,400 shares of the company’s stock, valued at $228,288. The trade was a 51.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Vivaldi sold 3,000 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $40.00, for a total value of $120,000.00. Following the sale, the director owned 19,225 shares in the company, valued at approximately $769,000. This trade represents a 13.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Crinetics Pharmaceuticals to a “hold” rating in a report on Saturday. Cantor Fitzgerald reiterated a “neutral” rating on shares of Crinetics Pharmaceuticals in a report on Wednesday, September 2nd. HC Wainwright lowered Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating and increased their price objective for the stock from $81.00 to $85.00 in a research report on Tuesday, July 7th. TD Cowen cut Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 8th. Finally, Robert W. Baird lifted their target price on Crinetics Pharmaceuticals from $62.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Crinetics Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $81.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.